Turley James S

Director · C, NOC, PGEN, EMR

As of 2026-09-16, Turley James S has 34 Form 4 transactions on record across 4 companies — 18 in the trailing 12 months.

Everything this person has disclosed to the SEC on Form 4 — across every company they file for — reconstructed from the public record. A filing history, not a tip sheet.

Reconstructed holdings

Direct: $13.1MIndirect: $5.2M$18.3Mas of 2026-09-16
  • Direct $13.1M
  • Indirect $5.2M
Cindirect39,448 sh$5.2M
PGENdirect685,417 sh$5.1M
EMRdirect27,458 sh$4.0M
NOCdirect6,738 sh$3.6M
Cdirect2,812 sh$374K

Reconstructed from this person's own Form 4 filings — the total each filing reported owning afterward, priced at the close on the as-of date shown. A filed position can lag the real one.

Direct and indirect holdings (e.g. through a trust or fund) are tagged separately, as filed.

Trades by company

C · 16 trades
2026-07-01: Award / grant, 165 sh ($24K)2026-07-01: Award / grant, 5 sh ($762)2026-04-01: Award / grant, 211 sh ($23K)2026-04-01: Award / grant, 7 sh ($758)2026-01-02: Award / grant, 185 sh ($22K)2026-01-02: Award / grant, 11 sh ($1K)2026-01-02: Award / grant, 1,263 sh ($0)2025-10-01: Award / grant, 214 sh ($22K)2025-10-01: Award / grant, 13 sh ($1K)2025-07-01: Award / grant, 243 sh ($20K)2025-07-01: Award / grant, 14 sh ($1K)2025-04-01: Award / grant, 279 sh ($20K)2025-04-01: Award / grant, 16 sh ($1K)2025-01-02: Award / grant, 259 sh ($18K)2025-01-02: Award / grant, 24 sh ($2K)2025-01-02: Award / grant, 2,118 sh ($0)
PGEN · 12 trades
2026-03-13: Option exercise, 71,839 sh ($0)2026-03-13: Option exercise, 71,839 sh2026-03-13: Option exercise, 71,839 sh2026-03-10: Award / grant, 17,806 sh ($62K)2026-03-10: Award / grant, 41,073 sh ($0)2026-03-10: Award / grant, 35,612 sh ($0)2025-03-14: Option exercise, 87,412 sh ($0)2025-03-14: Option exercise, 87,412 sh2025-03-14: Option exercise, 87,412 sh2025-03-13: Award / grant, 35,919 sh ($62K)2025-03-13: Award / grant, 83,517 sh ($0)2025-03-13: Award / grant, 71,839 sh ($0)
EMR · 4 trades
2026-02-03: Award / grant, 1,251 sh2026-02-03: Award / grant, 1,251 sh2025-02-04: Award / grant, 1,476 sh2025-02-04: Award / grant, 1,476 sh
NOC · 2 trades
2026-05-20: Award / grant, 349 sh ($193K)2025-05-21: Award / grant, 385 sh ($182K)

Filing ledger

DateCompanyActionShares @ priceValueOwnership ΔOwned afterFiling
34 award / exercise / gift records — not counted as purchases
DateCompanyActionSharesOwned afterFiling
2026-07-01CAward / grant16539,448Form 4
2026-07-01CAward / grant52,812Form 4
2026-05-20NOCAward / grant3496,738Form 4
2026-04-01CAward / grant21139,283Form 4
2026-04-01CAward / grant72,806Form 4
2026-03-13PGENOption exercise71,8390Form 4
2026-03-13PGENOption exercise71,839685,417Form 4
2026-03-13PGENOption exercise71,839685,417Form 4
2026-03-10PGENAward / grant17,806613,578Form 4
2026-03-10PGENAward / grant41,07341,073Form 4
2026-03-10PGENAward / grant35,61235,612Form 4
2026-02-03EMRAward / grant1,25127,458Form 4
2026-02-03EMRAward / grant1,25127,458Form 4
2026-01-02CAward / grant18539,071Form 4
2026-01-02CAward / grant112,800Form 4
2026-01-02CAward / grant1,2634,961Form 4
2025-10-01CAward / grant21436,714Form 4
2025-10-01CAward / grant133,698Form 4
2025-07-01CAward / grant24336,500Form 4
2025-07-01CAward / grant143,686Form 4
2025-05-21NOCAward / grant3856,297Form 4
2025-04-01CAward / grant27936,257Form 4
2025-04-01CAward / grant163,671Form 4
2025-03-14PGENOption exercise87,4120Form 4
2025-03-14PGENOption exercise87,412595,772Form 4
2025-03-14PGENOption exercise87,412595,772Form 4
2025-03-13PGENAward / grant35,919508,360Form 4
2025-03-13PGENAward / grant83,51783,517Form 4
2025-03-13PGENAward / grant71,83971,839Form 4
2025-02-04EMRAward / grant1,47626,207Form 4
2025-02-04EMRAward / grant1,47626,207Form 4
2025-01-02CAward / grant25935,978Form 4
2025-01-02CAward / grant2435,719Form 4
2025-01-02CAward / grant2,1183,655Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.